Cardiovascular Outcomes with Ertugliflozin in Type 2 Diabetes
Open accessThe DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
Abstract
BACKGROUND: The cardiovascular effects of ertugliflozin, an inhibitor of sodium-glucose cotransporter 2, have not been established. METHODS: In a multicenter, double-blind trial, we randomly assigned patients with type 2 diabetes and atherosclerotic cardiovascular disease to receive 5 mg or 15 mg of ertugliflozin or placebo once daily. With the data from the two ertugliflozin dose groups pooled for analysis, the primary objective was to show the noninferiority of ertugliflozin to placebo with respect to the primary outcome, major adverse cardiovascular events (a composite of death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke). The noninferiority margin was 1.3 (upper boundary of a 95.6% confidence interval for the hazard ratio [ertugliflozin vs. placebo] for major adverse cardiovascular events). The first key secondary outcome was a composite of death from cardiovascular causes or hospitalization for heart failure. RESULTS: A total of 8246 patients underwent randomization and were followed for a mean of 3.5 years. Among 8238 patients who received at least one dose of ertugliflozin or placebo, a major adverse cardiovascular event occurred in 653 of 5493 patients (11.9%) in the ertugliflozin group and in 327 of 2745 patients (11.9%) in the placebo group (hazard ratio, 0.97; 95.6% confidence interval [CI], 0.85 to 1.11; P<0.001 for noninferiority). Death from cardiovascular causes or hospitalization for heart failure occurred in 444 of 5499 patients (8.1%) in the ertugliflozin group and in 250 of 2747 patients (9.1%) in the placebo group (hazard ratio, 0.88; 95.8% CI, 0.75 to 1.03; P = 0.11 for superiority). The hazard ratio for death from cardiovascular causes was 0.92 (95.8% CI, 0.77 to 1.11), and the hazard ratio for death from renal causes, renal replacement therapy, or doubling of the serum creatinine level was 0.81 (95.8% CI, 0.63 to 1.04). Amputations were performed in 54 patients (2.0%) who received the 5-mg dose of ertugliflozin and in 57 patients (2.1%) who received the 15-mg dose, as compared with 45 patients (1.6%) who received placebo. CONCLUSIONS: Among patients with type 2 diabetes and atherosclerotic cardiovascular disease, ertugliflozin was noninferior to placebo with respect to major adverse cardiovascular events. (Funded by Merck Sharp & Dohme and Pfizer; VERTIS CV ClinicalTrials.gov number, NCT01986881.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The trial of once-weekly exenatide demonstrated a directionally favorable effect on MACE but narrowly missed statistical significance.644”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [644]
In the citing paper
“In the CVOTs Harmony Outcomes (albiglutide vs placebo), EXSCEL (exenatide LA vs placebo), and AMPLITUDE-O (efpeglenatide vs placebo), there were numerically fewer strokes, but HRs were not significant.472,641,644”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [644]
In the citing paper
“The SGLT2i cardiovascular outcome trials (CVOTs) have reported DKA rates of 0.1 -0.6% compared with rates of < 0.1 -0.3% with placebo (143 -147), with very low rates in the HF (148 -151) and CKD (152,153) outcome studies.”
In the citing paper
“In the Evaluation of Ertugli fl ozin Ef fi cacy and Safety CVOT (VERTIS CV), which recruited exclusively people with established CVD and type 2 diabetes, ertugli fl ozin was similar to placebo with respect to the primary MACE outcome and all key secondary outcomes (including a composite kidney outcome) except for HHF (146).”
In the citing paper
“While there was a trend for bene fi t for the key secondary endpoint of cardiovascular death or heart failure hospitalization, this did not meet statistical signi fi cance (HR: 0.88; 95% CI: 0.75 -1.03).”
From KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease (2022) · cites this paper as [91]
18 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Zinman, B., Wanner, C., Lachin, J. M., Fitchett, D., Bluhmki, E., Hantel, S., Mattheus, M., Devins, T., Johansen, O. E., Woerle, H. J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504720 · Cited by 12,315
Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
Neal, B., Perkovic, V., Mahaffey, K. W., de Zeeuw, D., Fulcher, G., Erondu, N., Shaw, W., Law, G., Desai, M., & Matthews, D. R. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1611925 · Cited by 7,830
Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
Wiviott, S. D., Raz, I., Bonaca, M. P., Mosenzon, O., Kato, E. T., Cahn, A., Silverman, M. G., Zelniker, T. A., Kuder, J. F., Murphy, S. A., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1812389 · Cited by 6,382
Self-citationCanagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy
Perkovic, V., Jardine, M. J., Neal, B., Bompoint, S., Heerspink, H. J. L., Charytan, D. M., Edwards, R., Agarwal, R., Bakris, G., Bull, S., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1811744 · Cited by 6,189
Self-citationEmpagliflozin and Progression of Kidney Disease in Type 2 Diabetes
Wanner, C., Inzucchi, S. E., Lachin, J. M., Fitchett, D., von Eynatten, M., Mattheus, M., Johansen, O. E., Woerle, H. J., Broedl, U. C., & Zinman, B. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1515920 · Cited by 3,655
Mortality and cardiovascular disease in type 1 and type 2 diabetes
Rawshani, A., Rawshani, A., Franzén, S., Eliasson, B., Svensson, A.-M., Miftaraj, M., McGuire, D. K., Sattar, N., Rosengren, A., & Gudbjörnsdottir, S. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1608664 · Cited by 1,389
Self-citationKDOQI clinical practice guideline for diabetes and CKD: 2012 update
(2012) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2012.07.005 · Cited by 1,320
Changing epidemiology of type 2 diabetes mellitus and associated chronic kidney disease
Thomas, M. C., Cooper, M. E., & Zimmet, P. (2016) · Nature Reviews Nephrology · doi:10.1038/nrneph.2015.173 · Cited by 742
Interim analysis: The alpha spending function approach
Demets, D. L., & Lan, K. K. G. (1994) · Statistics in Medicine · doi:10.1002/sim.4780131308 · Cited by 564
Cannon, C. P., McGuire, D. K., Pratley, R., Dagogo-Jack, S., Mancuso, J., Huyck, S., Charbonnel, B., Shih, W. J., Gallo, S., Masiukiewicz, U., et al. (2018) · American Heart Journal · doi:10.1016/j.ahj.2018.08.016 · Cited by 203
Self-citation
Research works printed but not linked: 1
- Food and Drug Administration. Guidance for industry: diabetes mellitus — evaluating cardiovascular risk in new antidiabetic therapies to treat type 2 diabetes. Fed Regist 2008;73(245):77724-77725 (https://www.govinfo.gov/content/pkg/FR-2008-12-19/pdf/E8-30086.pdf).
Cited by
2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure
McDonagh, T. A., Metra, M., Adamo, M., Gardner, R. S., Baumbach, A., Böhm, M., Burri, H., Butler, J., Čelutkienė, J., Chioncel, O., et al. (2021) · European Heart Journal · doi:10.1093/eurheartj/ehab368 · Cited by 13,344
2021 ESC Guidelines on cardiovascular disease prevention in clinical practice
Visseren, F. L. J., Mach, F., Smulders, Y. M., Carballo, D., Koskinas, K. C., Bäck, M., Benetos, A., Biffi, A., Boavida, J.-M., Capodanno, D., et al. (2021) · European Heart Journal · doi:10.1093/eurheartj/ehab484 · Cited by 6,485
Self-citation2024 ESC Guidelines for the management of chronic coronary syndromes
Vrints, C., Andreotti, F., Koskinas, K. C., Rossello, X., Adamo, M., Ainslie, J., Banning, A. P., Budaj, A., Buechel, R. R., Chiariello, G. A., et al. (2024) · European Heart Journal · doi:10.1093/eurheartj/ehae177 · Cited by 2,774
Authors/Task Force Members:, McDonagh, T. A., Metra, M., Adamo, M., Gardner, R. S., Baumbach, A., Böhm, M., Burri, H., Butler, J., Čelutkienė, J., et al. (2022) · European Journal of Heart Failure · doi:10.1002/ejhf.2333 · Cited by 2,171
Davies, M. J., Aroda, V. R., Collins, B. S., Gabbay, R. A., Green, J., Maruthur, N. M., Rosas, S. E., Del Prato, S., Mathieu, C., Mingrone, G., et al. (2022) · Diabetes Care · doi:10.2337/dci22-0034 · Cited by 2,104
“Pairwise meta-analyses of SGLT2i CVOTs verified that SGLT2i reduced MACE, HHF, and a composite kidney outcome in the overall population versus placebo (142,249).”
MethodInfluentialSotagliflozin in patients with diabetes and recent worsening heart failure
Bhatt, D. L., Szarek, M., Steg, P. G., Cannon, C. P., Leiter, L. A., McGuire, D. K., Lewis, J. B., Riddle, M. C., Voors, A. A., Metra, M., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2030183 · Cited by 1,868
Self-citation2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes.
Marx, N., Federici, M., Schütt, K., Müller-Wieland, D., Ajjan, R. A., Antunes, M. J., Christodorescu, R. M., Crawford, C., Di Angelantonio, E., Eliasson, B., et al. (2023) · European Heart Journal · doi:10.1093/eurheartj/ehad192 · Cited by 1,642
Self-citationVirani, S. S., Newby, L. K., Arnold, S. V., Bittner, V., Brewer, L. C., Demeter, S. H., Dixon, D. L., Fearon, W. F., Hess, B., Johnson, H. M., et al. (2023) · Circulation · doi:10.1161/cir.0000000000001168 · Cited by 1,598
KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease
Rossing, P., Caramori, M. L., Chan, J. C. N., Heerspink, H. J. L., Hurst, C., Khunti, K., Liew, A., Michos, E. D., Navaneethan, S. D., Olowu, W. A., et al. (2022) · Kidney International · doi:10.1016/j.kint.2022.06.008 · Cited by 1,373
McGuire, D. K., Shih, W. J., Cosentino, F., Charbonnel, B., Cherney, D. Z. I., Dagogo-Jack, S., Pratley, R., Greenberg, M., Wang, S., Huyck, S., et al. (2021) · JAMA Cardiology · doi:10.1001/jamacardio.2020.4511 · Cited by 1,235
Self-citationSotagliflozin in patients with diabetes and chronic kidney disease
Bhatt, D. L., Szarek, M., Pitt, B., Cannon, C. P., Leiter, L. A., McGuire, D. K., Lewis, J. B., Riddle, M. C., Inzucchi, S. E., Kosiborod, M. N., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2030186 · Cited by 1,205
Self-citationInflammation and atherosclerosis: signaling pathways and therapeutic intervention
Kong, P., Cui, Z.-Y., Huang, X.-F., Zhang, D.-D., Guo, R.-J., & Han, M. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-00955-7 · Cited by 1,183
“Ertugliflozin was demonstrated the noninferiority versus placebo on MACE in patients with atherosclerotic cardiovascular disease and T2DM.(334) Dapagliflozin treatment did not lead to lower or higher MACE compared to placebo in T2DM patients at risk for atherosclerotic cardiovascular disease rate but did decrease the…”
ResultInfluentialDavies, M. J., Aroda, V. R., Collins, B. S., Gabbay, R. A., Green, J., Maruthur, N. M., Rosas, S. E., Del Prato, S., Mathieu, C., Mingrone, G., et al. (2022) · Diabetologia · doi:10.1007/s00125-022-05787-2 · Cited by 1,048
“Sotagliflozin reduced the composite endpoint of cardiovascular mortality, HHF or urgent visits for HF compared with placebo, but had no effect on the composite kidney endpoint.”
InfluentialBaigent, C., Emberson, J., Haynes, R., Herrington, W. G., Judge, P., Landray, M. J., Mayne, K. J., Ng, S. Y. A., Preiss, D., Roddick, A. J., et al. (2022) · The Lancet · doi:10.1016/s0140-6736(22)02074-8 · Cited by 1,020
Self-citation10. Cardiovascular Disease and Risk Management: Standards of Medical Care in Diabetes—2022
American Diabetes Association Professional Practice Committee (2022) · Diabetes Care · doi:10.2337/dc22-s010 · Cited by 869
“The Evaluation of Ertugliflozin Efficacy and Safety Cardiovascular Outcomes Trial (VERTIS CV) (192) was a randomized, double-blind trial that established the effects of ertugliflozin versus placebo on cardiovascular outcomes in 8,246 patients with type 2 diabetes and established ASCVD.”
BackgroundType 2 diabetes mellitus in adults: pathogenesis, prevention and therapy
Lu, X., Xie, Q., Pan, X., Zhang, R., Zhang, X., Peng, G., Zhang, Y., Shen, S., & Tong, N. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01951-9 · Cited by 665
Gornik, H. L., Aronow, H. D., Goodney, P. P., Arya, S., Brewster, L. P., Byrd, L., Chandra, V., Drachman, D. E., Eaves, J. M., Ehrman, J. K., et al. (2024) · Circulation · doi:10.1161/cir.0000000000001251 · Cited by 771
Joseph, J. J., Deedwania, P., Acharya, T., Aguilar, D., Bhatt, D. L., Chyun, D. A., Di Palo, K. E., Golden, S. H., Sperling, L. S., & on behalf of the American Heart Association Diabetes Committee of the Council on Lifestyle and Cardiometabolic Health; Council on Arteriosclerosis, T. A. V. B. C. O. C. C. A. C. O. H. (2022) · Circulation · doi:10.1161/cir.0000000000001040 · Cited by 660
Virani, S. S., Newby, L. K., Arnold, S. V., Bittner, V., Brewer, L. C., Demeter, S. H., Dixon, D. L., Fearon, W. F., Hess, B., Johnson, H. M., et al. (2023) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2023.04.003 · Cited by 596
SGLT2 inhibitors and GLP-1 receptor agonists: established and emerging indications
Brown, E., Heerspink, H. J. L., Cuthbertson, D. J., & Wilding, J. P. H. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00536-5 · Cited by 581
2021 ESC Guidelines on cardiovascular disease prevention in clinical practice
Visseren, F. L. J., Mach, F., Smulders, Y. M., Carballo, D., Koskinas, K. C., Bäck, M., Benetos, A., Biffi, A., Boavida, J.-M., Capodanno, D., et al. (2022) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwab154 · Cited by 542
Self-citationBlonde, L., Umpierrez, G. E., Reddy, S. S., McGill, J. B., Berga, S. L., Bush, M., Chandrasekaran, S., DeFronzo, R. A., Einhorn, D., Galindo, R. J., et al. (2022) · Endocrine Practice · doi:10.1016/j.eprac.2022.08.002 · Cited by 507
10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2025
American Diabetes Association Professional Practice Committee, ElSayed, N. A., McCoy, R. G., Aleppo, G., Balapattabi, K., Beverly, E. A., Briggs Early, K., Bruemmer, D., Das, S. R., Echouffo-Tcheugui, J. B., et al. (2025) · Diabetes Care · doi:10.2337/dc25-s010 · Cited by 486
10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2023
ElSayed, N. A., Aleppo, G., Aroda, V. R., Bannuru, R. R., Brown, F. M., Bruemmer, D., Collins, B. S., Das, S. R., Hilliard, M. E., Isaacs, D., et al. (2023) · Diabetes Care · doi:10.2337/dc23-s010 · Cited by 465
Self-citationCardiovascular disease in type 2 diabetes mellitus: progress toward personalized management
Ma, C.-X., Ma, X.-N., Guan, C.-H., Li, Y.-D., Mauricio, D., & Fu, S.-B. (2022) · Cardiovascular Diabetology · doi:10.1186/s12933-022-01516-6 · Cited by 464
10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2024
American Diabetes Association Professional Practice Committee, ElSayed, N. A., Aleppo, G., Bannuru, R. R., Bruemmer, D., Collins, B. S., Das, S. R., Ekhlaspour, L., Hilliard, M. E., Johnson, E. L., et al. (2024) · Diabetes Care · doi:10.2337/dc24-s010 · Cited by 438
Self-citationPacker, M., Anker, S. D., Butler, J., Filippatos, G., Ferreira, J. P., Pocock, S. J., Carson, P., Anand, I., Doehner, W., Haass, M., et al. (2021) · Circulation · doi:10.1161/circulationaha.120.051783 · Cited by 435
Pop-Busui, R., Januzzi, J. L., Bruemmer, D., Butalia, S., Green, J. B., Horton, W. B., Knight, C., Levi, M., Rasouli, N., & Richardson, C. R. (2022) · Diabetes Care · doi:10.2337/dci22-0014 · Cited by 399
Wheeler, D. C., Toto, R. D., Stefánsson, B. V., Jongs, N., Chertow, G. M., Greene, T., Hou, F. F., McMurray, J. J. V., Pecoits-Filho, R., Correa-Rotter, R., et al. (2021) · Kidney International · doi:10.1016/j.kint.2021.03.033 · Cited by 420
Packer, M., Butler, J., Zannad, F., Filippatos, G., Ferreira, J. P., Pocock, S. J., Carson, P., Anand, I., Doehner, W., Haass, M., et al. (2021) · Circulation · doi:10.1161/circulationaha.121.056824 · Cited by 354
Neuroprotective effect of SGLT2 inhibitors.
Pawlos, A., Broncel, M., Woźniak, E., & Gorzelak-Pabiś, P. (2021) · Molecules · doi:10.3390/molecules26237213 · Cited by 304
“placebo in reducing cardiovascular mortality and other cardiovascular outcomes [13].”
BackgroundNeuen, B. L., Oshima, M., Agarwal, R., Arnott, C., Cherney, D. Z., Edwards, R., Langkilde, A. M., Mahaffey, K. W., McGuire, D. K., Neal, B., et al. (2022) · Circulation · doi:10.1161/circulationaha.121.057736 · Cited by 290
Self-citationGornik, H. L., Aronow, H. D., Goodney, P. P., Arya, S., Brewster, L. P., Byrd, L., Chandra, V., Drachman, D. E., Eaves, J. M., Ehrman, J. K., et al. (2024) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2024.02.013 · Cited by 294
Yun, J.-S., & Ko, S.-H. (2021) · Metabolism · doi:10.1016/j.metabol.2021.154838 · Cited by 292
Rossing, P., Caramori, M. L., Chan, J. C. N., Heerspink, H. J. L., Hurst, C., Khunti, K., Liew, A., Michos, E. D., Navaneethan, S. D., Olowu, W. A., et al. (2022) · Kidney International · doi:10.1016/j.kint.2022.06.013 · Cited by 274
Gliflozins in the Management of Cardiovascular Disease
Braunwald, E. (2022) · New England Journal of Medicine · doi:10.1056/nejmra2115011 · Cited by 266
An Overview of the Cardiorenal Protective Mechanisms of SGLT2 Inhibitors
Salvatore, T., Galiero, R., Caturano, A., Rinaldi, L., Di Martino, A., Albanese, G., Di Salvo, J., Epifani, R., Marfella, R., Docimo, G., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23073651 · Cited by 256
“Ertugliflozin VERTIS CV study [92] 8246 T2DM patients with established CV disease and eGFR ≥ 30 mL/min/ 1.”
BackgroundRenal Protection with SGLT2 Inhibitors: Effects in Acute and Chronic Kidney Disease
Bailey, C. J., Day, C., & Bellary, S. (2022) · Current Diabetes Reports · doi:10.1007/s11892-021-01442-z · Cited by 248
“In the VERTIS CV trial, the renal composite, which did not include a measure of eGFR (doubling of the serum creatinine, starting renal replacement therapy or death from a renal cause), was numerically reduced by 19% (not statistically significantly) with use of ertugliflozin [44].”
BackgroundNavaneethan, S. D., Zoungas, S., Caramori, M. L., Chan, J. C. N., Heerspink, H. J. L., Hurst, C., Liew, A., Michos, E. D., Olowu, W. A., Sadusky, T., et al. (2023) · Annals of Internal Medicine · doi:10.7326/m22-2904 · Cited by 248
Cosentino, F., Cannon, C. P., Cherney, D. Z. I., Masiukiewicz, U., Pratley, R., Dagogo-Jack, S., Frederich, R., Charbonnel, B., Mancuso, J., Shih, W. J., et al. (2020) · Circulation · doi:10.1161/circulationaha.120.050255 · Cited by 242
Self-citationUpdate on the pathophysiology and medical treatment of peripheral artery disease
Golledge, J. (2022) · Nature Reviews Cardiology · doi:10.1038/s41569-021-00663-9 · Cited by 233
Protective Factors and the Pathogenesis of Complications in Diabetes
Yu, M. G., Gordin, D., Fu, J., Park, K., Li, Q., & King, G. L. (2024) · Endocrine Reviews · doi:10.1210/endrev/bnad030 · Cited by 228
Yau, K., Dharia, A., Alrowiyti, I., & Cherney, D. Z. I. (2022) · Kidney International Reports · doi:10.1016/j.ekir.2022.04.094 · Cited by 223
Self-citation2021 Clinical Practice Guidelines for Diabetes Mellitus of the Korean Diabetes Association
Hur, K. Y., Moon, M. K., Park, J. S., Kim, S.-K., Lee, S.-H., Yun, J.-S., Baek, J. H., Noh, J., Lee, B.-W., Oh, T. J., et al. (2021) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2021.0156 · Cited by 226
“HF than placebo treatment regardless of the presence of diabetes [105-107].”
Background10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2026
American Diabetes Association Professional Practice Committee for Diabetes*, Bajaj, M., McCoy, R. G., Balapattabi, K., Bannuru, R. R., Bellini, N. J., Bennett, A. K., Beverly, E. A., Briggs Early, K., ChallaSivaKanaka, S., et al. (2026) · Diabetes Care · doi:10.2337/dc26-s010 · Cited by 225
Cardiovascular disease in diabetes, beyond glucose
Eckel, R. H., Bornfeldt, K. E., & Goldberg, I. J. (2021) · Cell Metabolism · doi:10.1016/j.cmet.2021.07.001 · Cited by 212
Patel, S. M., Kang, Y. M., Im, K., Neuen, B. L., Anker, S. D., Bhatt, D. L., Butler, J., Cherney, D. Z. I., Claggett, B. L., Fletcher, R. A., et al. (2024) · Circulation · doi:10.1161/circulationaha.124.069568 · Cited by 198
Self-citationMetabolism at the crossroads of inflammation and fibrosis in chronic kidney disease
Miguel, V., Shaw, I. W., & Kramann, R. (2025) · Nature Reviews Nephrology · doi:10.1038/s41581-024-00889-z · Cited by 181
“Although these drugs were initially developed for diabetes, their beneficial role in CKD and heart failure became evident and multiple SGLT2 inhibitors have proven to be beneficial in clinical trials in patients with and without diabetes 162–165 .”
Anker, S. D., Usman, M. S., Anker, M. S., Butler, J., Böhm, M., Abraham, W. T., Adamo, M., Chopra, V. K., Cicoira, M., Cosentino, F., et al. (2023) · European Journal of Heart Failure · doi:10.1002/ejhf.2894 · Cited by 201
Self-citationThe current role of sodium-glucose cotransporter 2 inhibitors in type 2 diabetes mellitus management
Xu, B., Li, S., Kang, B., & Zhou, J. (2022) · Cardiovascular Diabetology · doi:10.1186/s12933-022-01512-w · Cited by 190
“VERTIS CV [11] T2DM patients with atherosclerotic CV disease 3.”
BackgroundResultInfluentialSGLT-2 Inhibitors in Heart Failure: A Review of Current Evidence
Talha, K. M., Anker, S. D., & Butler, J. (2023) · International Journal of Heart Failure · doi:10.36628/ijhf.2022.0030 · Cited by 185
SGLT2 inhibitors: from glucose-lowering to cardiovascular benefits
Preda, A., Montecucco, F., Carbone, F., Camici, G. G., Lüscher, T. F., Kraler, S., & Liberale, L. (2024) · Cardiovascular Research · doi:10.1093/cvr/cvae047 · Cited by 161
JCS/JHFS 2021 Guideline Focused Update on Diagnosis and Treatment of Acute and Chronic Heart Failure
Tsutsui, H., Ide, T., Ito, H., Kihara, Y., Kinugawa, K., Kinugawa, S., Makaya, M., Murohara, T., Node, K., Saito, Y., et al. (2021) · Circulation Journal · doi:10.1253/circj.cj-21-0431 · Cited by 183
Sodium-glucose co-transporter 2 inhibitor therapy: mechanisms of action in heart failure
Joshi, S. S., Singh, T., Newby, D. E., & Singh, J. (2021) · Heart · doi:10.1136/heartjnl-2020-318060 · Cited by 178
Cognitive impairment and type 2 diabetes mellitus: Focus of SGLT2 inhibitors treatment
Rizzo, M. R., Di Meo, I., Polito, R., Auriemma, M. C., Gambardella, A., di Mauro, G., Capuano, A., & Paolisso, G. (2022) · Pharmacological Research · doi:10.1016/j.phrs.2022.106062 · Cited by 178
Kidney and heart failure outcomes associated with SGLT2 inhibitor use
van der Aart-van der Beek, A. B., de Boer, R. A., & Heerspink, H. J. L. (2022) · Nature Reviews Nephrology · doi:10.1038/s41581-022-00535-6 · Cited by 173
Tsapas, A., Karagiannis, T., Kakotrichi, P., Avgerinos, I., Mantsiou, C., Tousinas, G., Manolopoulos, A., Liakos, A., Malandris, K., Matthews, D. R., et al. (2021) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14451 · Cited by 179
Epidemiology, Pathophysiology, Diagnosis and Treatment of Heart Failure in Diabetes
Park, J. J. (2021) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2020.0282 · Cited by 171
“In the Valsartan Heart Failure Trial (Val-HeFT) with patients with LVEF <40%, valsartan 160 mg twice daily reduced the composite endpoint of mortality and morbidity, defined as the incidence of cardiac arrest with resuscitation, hospitalization for HF (HHF), or receipt of intravenous inotropic or vasodilator therapy c…”
BackgroundInfluentialSteatotic liver disease, MASLD and risk of chronic kidney disease
Bilson, J., Mantovani, A., Byrne, C. D., & Targher, G. (2024) · Diabetes & Metabolism · doi:10.1016/j.diabet.2023.101506 · Cited by 166
on behalf of the VERTIS CV Investigators, Cherney, D. Z. I., Charbonnel, B., Cosentino, F., Dagogo-Jack, S., McGuire, D. K., Pratley, R., Shih, W. J., Frederich, R., Maldonado, M., et al. (2021) · Diabetologia · doi:10.1007/s00125-021-05407-5 · Cited by 168
“In the VERTIS CV study, the secondary outcome of a kidney composite involving a doubling of creatinine did not reach statistical significance [12].”
BackgroundMethodSelf-citationCanadian Stroke Best Practice Recommendations: Secondary Prevention of Stroke Update 2020
Gladstone, D. J., Lindsay, M. P., Douketis, J., Smith, E. E., Dowlatshahi, D., Wein, T., Bourgoin, A., Cox, J., Falconer, J. B., Graham, B. R., et al. (2022) · Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques · doi:10.1017/cjn.2021.127 · Cited by 168
Cardoso, R., Graffunder, F. P., Ternes, C. M. P., Fernandes, A., Rocha, A. V., Fernandes, G., & Bhatt, D. L. (2021) · EClinicalMedicine · doi:10.1016/j.eclinm.2021.100933 · Cited by 157
“Evidence of cardiovascular benefit with these agents led to the undertaking of large cardiovascular outcome trials, which have consistently shown a reduction in the composite of cardiovascular mortality or HF hospitalizations with SGLT2 inhibitors in patients with diabetes [8-15].”
BackgroundInfluentialEffect of SGLT2 Inhibitors on Cardiovascular Outcomes Across Various Patient Populations
Usman, M., Siddiqi, T. J., Anker, S. D., Bakris, G. L., Bhatt, D. L., Filippatos, G. S., Fonarow, G. C., Greene, S. J., Januzzi, J. L., Khan, M. S., et al. (2023) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2023.04.034 · Cited by 187
Self-citationSchernthaner, G., Shehadeh, N., Ametov, A. S., Bazarova, A. V., Ebrahimi, F., Fasching, P., Janež, A., Kempler, P., Konrāde, I., Lalić, N. M., et al. (2020) · Cardiovascular Diabetology · doi:10.1186/s12933-020-01154-w · Cited by 164
Diabetic nephropathy: Focusing on pathological signals, clinical treatment, and dietary regulation
Hu, Q., Chen, Y., Deng, X., Li, Y., Ma, X., Zeng, J., & Zhao, Y. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.114252 · Cited by 162
Yamada, T., Wakabayashi, M., Bhalla, A., Chopra, N., Miyashita, H., Mikami, T., Ueyama, H., Fujisaki, T., Saigusa, Y., Yamaji, T., et al. (2021) · Cardiovascular Diabetology · doi:10.1186/s12933-020-01197-z · Cited by 159
JCS/JHFS 2021 Guideline Focused Update on Diagnosis and Treatment of Acute and Chronic Heart Failure
Tsutsui, H., Ide, T., Ito, H., Kihara, Y., Kinugawa, K., Kinugawa, S., Makaya, M., Murohara, T., Node, K., Saito, Y., et al. (2021) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2021.04.023 · Cited by 158
Pharmacotherapy of type 2 diabetes: An update and future directions
DeMarsilis, A. J., Reddy, N., Boutari, C., Filippaios, A., Sternthal, E., Katsiki, N., & Mantzoros, C. S. (2022) · Metabolism · doi:10.1016/j.metabol.2022.155332 · Cited by 184
Atualização de Tópicos Emergentes da Diretriz Brasileira de Insuficiência Cardíaca – 2021
Marcondes‐Braga, F. G., Moura, L. Z., Issa, V. S., Vieira, J. L., Rohde, L. E. P., Simões, M. V., Fernandes-Silva, M. M., Rassi, S., Martins, S. M., de Albuquerque, D. C., et al. (2021) · Arquivos Brasileiros de Cardiologia · doi:10.36660/abc.20210367 · Cited by 245
Guideline recommendations and the positioning of newer drugs in type 2 diabetes care
Marx, N., Davies, M. J., Grant, P. J., Mathieu, C., Petrie, J. R., Cosentino, F., & Buse, J. B. (2020) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(20)30343-0 · Cited by 180
Self-citationLiu, Z., Ma, X., Ilyas, I., Zheng, X., Luo, S., Little, P. J., Kamato, D., Sahebkar, A., Wu, W., Weng, J., et al. (2021) · Theranostics · doi:10.7150/thno.54498 · Cited by 155
“The favorable clinical outcomes are hypothesized to be mainly driven by reduction of the rate of HHF.”
BackgroundInfluentialKazé, A. D., Zhuo, M., Kim, S. C., Patorno, E., & Paik, J. M. (2022) · Cardiovascular Diabetology · doi:10.1186/s12933-022-01476-x · Cited by 173
“CI indicates confidence interval; HHF hospitalization for heart failure, HR hazard ratio, I2, I-squared, MACE Major Adverse Cardiovascular Events, MI myocardial infarction, SCORED Effect of Sotagliflozin on Cardiovascular and Renal Events in Patients with Type 2 Diabetes and Moderate Renal Impairment Who Are at Cardio…”
MethodInfluentialPandey, A. K., Okaj, I., Kaur, H., Belley‐Cote, E. P., Wang, J., Oraii, A., Benz, A. P., Johnson, L. S. B., Young, J., Wong, J. A., et al. (2021) · Journal of the American Heart Association · doi:10.1161/jaha.121.022222 · Cited by 139
Karagiannis, T., Tsapas, A., Athanasiadou, E., Avgerinos, I., Liakos, A., Matthews, D. R., & Bekiari, E. (2021) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2021.108737 · Cited by 146
Usman, M., Bhatt, D. L., Hameed, I., Anker, S. D., CHENG, A. Y. Y., Hernandez, A. F., Jones, W. S., Khan, M. S., Petrie, M. C., Udell, J. A., et al. (2024) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(24)00102-5 · Cited by 166
Efficacy and Safety of SGLT2 Inhibitors in Heart Failure: Systematic Review and Meta-Analysis
Butler, J., Usman, M. S., Khan, M. S., Greene, S. J., Friede, T., Vaduganathan, M., Filippatos, G., Stewart Coats, A. J., & Anker, S. D. (2020) · ESC Heart Failure · doi:10.1002/ehf2.13169 · Cited by 138
“This included three HF-specific trials (DAPA-HF, EMPEROR-Reduced, and SOLOIST-WHF) and four cardiovascular outcome trials: CANVAS (CANagliflozin cardioVascular Assessment Study),(3) EMPA-REG OUTCOME (Empagliflozin Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients),(4) DECLARE-TIMI 58 (Multicenter…”
MethodGuía ESC 2021 sobre el diagnóstico y tratamiento de la insuficiencia cardiaca aguda y crónica
McDonagh, T. A., Metra, M., Adamo, M., Gardner, R. S., Baumbach, A., Böhm, M., Burri, H., Butler, J., Čelutkienė, J., Chioncel, O. D., et al. (2022) · Revista Española de Cardiología · doi:10.1016/j.recesp.2021.11.027 · Cited by 177
Scisciola, L., Cataldo, V., Taktaz, F., Fontanella, R. A., Pesapane, A., Ghosh, P., Franzese, M., Puocci, A., Angelis, A. D., Sportiello, L., et al. (2022) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2022.1008922 · Cited by 141
Marilly, E., Cottin, J., Cabrera, N., Cornu, C., Boussageon, R., Moulin, P., Lega, J., Gueyffier, F., Cucherat, M., & Grenet, G. (2022) · Diabetologia · doi:10.1007/s00125-022-05773-8 · Cited by 138
“Two trials tested canagliflozin (CANVAS Program [2] and CREDENCE [3]), one tested dapagliflozin (DECLARE-TIMI 58 [4]), one tested empagliflozin (EMPA-REG OUTCOME [5]) and one tested ertugliflozin (VERTIS-CV [41]).”
MethodInfluentialPersonalized type 2 diabetes management: an update on recent advances and recommendations
Williams, D. M., Jones, H., & Stephens, J. W. (2022) · Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy · doi:10.2147/dmso.s331654 · Cited by 121
Impact of SGLT2 Inhibitors on Heart Failure: From Pathophysiology to Clinical Effects
Palmiero, G., Cesaro, A., Vetrano, E., Pafundi, P. C., Galiero, R., Caturano, A., Moscarella, E., Gragnano, F., Salvatore, T., Rinaldi, L., et al. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22115863 · Cited by 110
“Of note, the VERTIS-CV trial had the higher proportion of patients with HF (~24”
MethodInfluentialCardiorenal protection of SGLT2 inhibitors—Perspectives from metabolic reprogramming
Gao, Y.-M., Feng, S., Wen, Y., Tang, T., Wang, B., & Liu, B. (2022) · EBioMedicine · doi:10.1016/j.ebiom.2022.104215 · Cited by 137
Cardiovascular protection by SGLT2 inhibitors – Do anti-inflammatory mechanisms play a role?
Elrakaybi, A., Laubner, K., Zhou, Q., Hug, M. J., & Seufert, J. (2022) · Molecular Metabolism · doi:10.1016/j.molmet.2022.101549 · Cited by 124
Tsai, W.-H., Chuang, S.-M., Liu, S.-C., Lee, C.-C., Chien, M.-N., Leung, C.-H., Liu, S.-J., & Shih, H.-M. (2021) · Scientific Reports · doi:10.1038/s41598-021-94945-4 · Cited by 113
The effect of dapagliflozin on albuminuria in DECLARE-TIMI 58
Mosenzon, O., Wiviott, S. D., Heerspink, H. J. L., Dwyer, J. P., Cahn, A., Goodrich, E. L., Rozenberg, A., Schechter, M., Yanuv, I., Murphy, S. A., et al. (2021) · Diabetes Care · doi:10.2337/dc21-0076 · Cited by 113
Self-citationType 2 Diabetes and Myocardial Infarction: Recent Clinical Evidence and Perspective
Cui, J., Liu, Y., Li, Y. H., Xu, F., & Liu, Y. (2021) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2021.644189 · Cited by 124
Qiu, M., Ding, L., Zhang, M., & Zhou, H. (2021) · Diabetes and Vascular Disease Research · doi:10.1177/14791641211011016 · Cited by 123
Applications of SGLT2 inhibitors beyond glycaemic control
O’Hara, D. V., Lam, C. S. P., McMurray, J. J. V., Yi, T. W., HOCKING, S. L., Dawson, J., Raichand, S., Januszewski, A. S., & Jardine, M. (2024) · Nature Reviews Nephrology · doi:10.1038/s41581-024-00836-y · Cited by 129
“In addition to empagliflozin, three other SGLT2 inhibitors have been investigated in large CVOTs in people with T2DM; namely cana-gliflozin 62,74 , dapagliflozin 75 and ertugliflozin 76 .”
InfluentialGiugliano, D., Longo, M., Scappaticcio, L., Bellastella, G., Maiorino, M. I., & Esposito, K. (2021) · Cardiovascular Diabetology · doi:10.1186/s12933-021-01430-3 · Cited by 107
“VERTIS-CV compared ertugliflozin to placebo in 8246 patients with T2D and established CV disease [20].”
MethodLin, D. S.-H., Lee, J.-K., Hung, C.-S., & Chen, W.-J. (2021) · Diabetologia · doi:10.1007/s00125-021-05529-w · Cited by 108
Salah, H. M., Al'Aref, S. J., Khan, M. S., Al-Hawwas, M., Vallurupalli, S., Mehta, J. L., Mounsey, J. P., Greene, S. J., McGuire, D. K., Lopes, R. D., et al. (2021) · American Heart Journal · doi:10.1016/j.ahj.2020.10.064 · Cited by 110
Self-citationSodium Glucose Cotransporter-2 Inhibition for Acute Myocardial Infarction
Udell, J. A., Jones, W. S., Petrie, M. C., Harrington, J., Anker, S. D., Bhatt, D. L., Hernandez, A. F., & Butler, J. (2022) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2022.03.353 · Cited by 117
Effects of Dapagliflozin in Patients With Kidney Disease, With and Without Heart Failure
McMurray, J. J. V., Wheeler, D. C., Stefánsson, B. V., Jongs, N., Postmus, D., Correa‐Rotter, R., Chertow, G. M., Hou, F. F., Rossing, P. R., Sjöström, C. D., et al. (2021) · JACC Heart Failure · doi:10.1016/j.jchf.2021.06.017 · Cited by 116
“A series of large randomized controlled trials have demonstrated that sodium glucose cotransporter 2 (SGLT2) inhibitors reduce the risk of HF hospitalization in patients with type 2 diabetes mellitus, including those with CKD (8-12).”
BackgroundHeart failure in type 2 diabetes: current perspectives on screening, diagnosis and management
Ceriello, A., Catrinoiu, D., Chandramouli, C., Cosentino, F., Dombrowsky, A. C., Itzhak, B., Lalic, N. M., Prattichizzo, F., Schnell, O., Seferovic, P. M., et al. (2021) · Cardiovascular Diabetology · doi:10.1186/s12933-021-01408-1 · Cited by 123
Self-citationD’Andrea, E., Wexler, D. J., Kim, S. C., Paik, J. M., Alt, E. M., & Patorno, E. (2023) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2022.6664 · Cited by 116
Patorno, E., Htoo, P. T., Glynn, R. J., Schneeweiss, S., Wexler, D. J., Pawar, A., Bessette, L. G., Chin, K., Everett, B. M., & Kim, S. C. (2021) · Annals of Internal Medicine · doi:10.7326/m21-0893 · Cited by 103
Seferovic, P. M., Paulus, W. J., Rosano, G., Polovina, M. M., Petrie, M. C., Jhund, P. S., Tschöpe, C., Sattar, N. A., Piepoli, M. F., Papp, Z. L., et al. (2024) · European Journal of Heart Failure · doi:10.1002/ejhf.3347 · Cited by 142
“84 88 However, the trials were confined to patients with established atherosclerotic cardiovascular disease or with multiple risk factors, and the efficacy of SGLT2 inhibitors in patients at lower cardio-vascular risk is less clear.”
Self-citationGlucose-Lowering Drugs to Reduce Cardiovascular Risk in Type 2 Diabetes
Kalyani, R. R. (2021) · New England Journal of Medicine · doi:10.1056/nejmcp2000280 · Cited by 101
Mavrakanas, T. A., Tsoukas, M. A., Brophy, J. M., Sharma, A., & Gariani, K. (2023) · Scientific Reports · doi:10.1038/s41598-023-42989-z · Cited by 99
“Dapagliflozin was initiated with an eGFR as low as 25 ml/min/1.73m 2 and empagliflozin with an eGFR of 20 ml/ min/1.73m 23,25,26 .”
Lin, D. S.-H., Lee, J.-K., & Chen, W.-J. (2021) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgab274 · Cited by 97
Metadata
- Authors
- Cannon, C. P., Pratley, R., Dagogo-Jack, S., Mancuso, J., Huyck, S., Masiukiewicz, U., Charbonnel, B., Frederich, R., Gallo, S., Cosentino, F., Shih, W. J., Gantz, I., Terra, S. G., Cherney, D. Z. I., & McGuire, D. K.
- Affiliations
- Rutgers, The State University of New Jersey (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2020-10-08
- Volume
- 383
- Issue
- 15
- Pages
- 1425-1435
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W3089283105
- Cited by
- 1,514
- References
- 14
- Citations by year
- 2026: 126 · 2025: 177 · 2024: 231 · 2023: 269 · 2022: 298 · 2021: 364 · 2020: 47
- FWCI
- 184.60
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- IRIS Research product catalog (Sapienza University of Rome) (submittedVersion)
- Funders
- Pfizer
- Merck
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- ertugliflozin, SGLT2 inhibitors, type 2 diabetes, atherosclerotic cardiovascular disease, major adverse cardiovascular events, heart failure hospitalization, cardiovascular mortality, non-inferiority, renal safety, non-inferiority margin, myocardial infarction, stroke, renal replacement therapy, serum creatinine doubling, cardiovascular risk stratification
- MeSH terms
- Sodium-Glucose Transporter 2 Inhibitors, Aged, Cardiovascular Diseases, Diabetes Mellitus, Type 2, Diabetic Nephropathies, Double-Blind Method, Female, Hospitalization, Humans, Male, Middle Aged, Placebos, Bridged Bicyclo Compounds, Heterocyclic, Atherosclerosis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.